Faculty Bibliography

We reviewed 239 infrapopliteal reversed greater saphenous vein graft bypasses placed for critical ischemia over a 7-year period to determine the influence of vein diameter on graft patency and limb salvage. Grafts were assigned to four groups based on the minimum external diameter measured during operation: less than 3.0 mm, n = 18; 3.0 mm, n = 59; 3.5 mm, n = 67; and greater than or equal to 4.0 mm, n = 145. A pattern of increasing graft patency and limb salvage among the four groups was noted as the minimum external diameter increased from less than 3.0 mm to greater than or equal to 4.0 mm. When compared to the larger grafts greater than or equal to 4.0 mm, primary graft patency was significantly lower both for less than 3.0 mm grafts (0% for less than 3.0 mm vs 65% for greater than or equal to 4.0 mm at 3 years, p less than 0.001) and for long (greater than 45 cm) 3.0 mm grafts (38% for long 3.0 mm vs 75% for greater than or equal to 4.0 mm at 2 years, p less than 0.005). All 3.5 mm and short (less than 45 cm) 3.0 mm grafts had patency rates similar to greater than or equal to 4.0 mm veins. Thus long 3.0 mm and all less than 3.0 mm reversed saphenous vein grafts should be considered at high risk for failure. Veins with fibrotic, thick-walled segments identified during operation (n = 19) had patency rates significantly lower than nonfibrotic veins (n = 270; p less than 0.01), and this may play a role in the failure of some less than 3.0 mm minimum external diameter vein grafts

Prospective cost and reimbursement data were collected from 10 centers in various parts of the United States on 566 patients undergoing lower extremity arterial reconstructions for limb salvage and nonlimb salvage indications. Information for each patient was available on indication and type of procedure, length of stay, the type of hospital insurance, and hospital costs/charges. Diagnosis related group payments from each center were used to determine net gain or loss for each patient. Patients were classified as having claudication or critical ischemia (limb salvage). Reimbursements matched costs/charges for the claudication group; overall mean loss in this group was only $915 per patient. However, all centers had important losses in the limb salvage group. Reimbursements averaged 60% of costs/charges, with a mean loss of $8158 per patient and an overall loss for all 10 centers of $3,653,918. An effort to remedy this inequity is progressing via a dialogue between representatives of the Society for Vascular Surgery, the North American Chapter of the International Society for Cardiovascular Surgery, and the federal government

The value of HLA matching in cadaver renal transplantation (CRT) continues to be debated. It has recently been suggested that increased importance be given to HLA matching for the distribution of cadaver kidneys. Such a policy would add both delay and expense to CRT, which could be justified only by significantly improved results. The results of CRT in 252 cyclosporine treated adult patients transplanted at our institution from November 1984 to April 1989 were reviewed. Kidneys were initially transplanted into crossmatch-negative recipients based on waiting time, regardless of match. From October 1987, a points system, based on United Network for Organ Sharing (UNOS) criteria has been used. Eighty-four pts. with zero antigen match with their donors were compared with 168 pts. sharing 1-6 Ag. Actuarial graft and patient survival were determined by the cumulative life table method and compared using a log rank test. Our results indicated no statistically significant difference in graft survival because of better matching or mismatching. These findings are in keeping with our previously reported long-term results for non-CsA pts. Past predictions of improved graft survival based upon better matching at our institution have not fulfilled expectations, with the exception of 6 Ag matches. In conclusion, increased emphasis on HLA matching with fewer 'points' for poorer matches does not appear justifiable

Recent reports suggest that percutaneous transluminal angioplasty is a satisfactory alternative to surgical treatment of occlusion of the infrapopliteal arteries. To evaluate further the merits of percutaneous angioplasty of these vessels, we retrospectively analyzed the results of 57 procedures in 53 patients. Seventy-six infrapopliteal arteries were dilated: 26 anterior tibial arteries, 10 posterior tibial arteries, 18 peroneal arteries, and 22 tibioperoneal trunks. Thirty-three (62%) of the patients had concomitant angioplasties of the femoropopliteal arteries or vein grafts. There were three major complications (one death due to cardiac arrest 5 hr after the procedure and two puncture-site hematomas requiring surgery). Twenty minor complications did not affect clinical course. In the first 14 procedures (25%), tapered catheters were used, and technical success occurred in only four (29%). In the succeeding 43 procedures (75%), Gruentzig balloon catheters and low-profile balloons were used, and technical success occurred in 37 procedures (86%). Prompt clinical improvement was seen in 32 (80%) of 40 technically successful procedures. Prompt clinical improvement occurred in 28 (97%) of 29 procedures in which angioplasty restored straight-line flow to the foot (i.e., nonobstructed blood flow in at least one calf vessel that is narrowed by no more than 75% of its diameter). When such flow was not restored, clinical improvement occurred in only four (36%) of 11 cases (p less than .001). These results show that with current technology, infrapopliteal artery angioplasty is an effective and safe procedure. The greatest benefit is achieved when straight-line blood flow to the foot is restored

We have treated 30 patients requiring urgent or emergent vascular procedures in the first 6 weeks after a myocardial infarction (median 11 days) from 1977 through 1989. Forty operations were performed, including 28 lower extremity revascularizations, 10 major amputations and revisions, and two carotid endarterectomies. There were four postoperative deaths (three cardiac related) and two nonfatal reinfarctions. Cardiac complications did not correlate with age, interval from myocardial infarction to surgery within the initial 6 weeks, type of anesthesia, or complexity of operation. Twenty of 24 patients survived attempts at leg revascularization, with ultimate limb salvage in 16. Our cardiac complication rate of 17% (5/30 patients) was reasonably close to that predicted by the Goldman risk scale for classes II and III and significantly better than class IV and also better than that predicted by the Cooperman risk scale for vascular surgery, despite the more recent preoperative myocardial infarctions in our patients. We attribute our low morbidity and mortality to the extracavitary nature of the procedures and possibly to improvements in anesthetic and perioperative management. Patients requiring urgent revascularization for limb salvage should not be denied surgery on the basis of a recent myocardial infarction

Secondary interventions play an important role in achieving the ultimate goal of limb salvage after primary infrainguinal interventions fail. By employing the described strategies and principles for secondary arterial reconstructions below the inguinal ligament, good results in terms of patency of the reoperated primary reconstruction or the secondary reconstruction can be obtained with significantly augmented limb salvage at a low cost in operative morbidity and mortality. These results mandate that vascular surgeons maintain an aggressive attitude toward the use of these secondary operations when a primary procedure fails to achieve or maintain its intended goal and a patient is faced with imminent limb loss because of distal ischemia